Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 7/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344668 | 1.00 | CNR2 (0.53) | CNR2LMNAMAPTKDM4ENPC1 | |
| SCHEMBL3384559 | 0.88 | CNR2 (0.48) | CNR2LMNAMAPTKDM4ENPC1 | |
| SCHEMBL3384555 | 0.88 | CNR2 (0.48) | CNR2LMNAMAPTKDM4ENPC1 | |
| SCHEMBL345241 | 0.87 | CNR2 (0.49) | CNR2LMNAMAPTKDM4ENPC1 | |
| SCHEMBL345240 | 0.87 | CNR2 (0.49) | CNR2LMNAMAPTKDM4ENPC1 | |
| SCHEMBL345047 | 0.85 | CNR2 (0.47) | CNR2LMNAMAPTATMTP53 | |
| SCHEMBL345046 | 0.85 | CNR2 (0.47) | CNR2LMNAMAPTATMTP53 | |
| SCHEMBL3384757 | 0.84 | CNR2 (0.45) | CNR2LMNAMAPTKDM4ENPC1 | |
| SCHEMBL3384760 | 0.84 | CNR2 (0.45) | CNR2LMNAMAPTKDM4ENPC1 | |
| SCHEMBL3387127 | 0.84 | CNR2 (0.44) | CNR2LMNAMAPTKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338467-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20120015929-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | disclosed |
| US-8058293-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2274306-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20090247500-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009114566-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015929-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, OPRL1 | CNR2 2/4885LMNA 2401/4885MAPT 2705/4885 |
| US-20090247500-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, OPRL1 | CNR2 2/4885LMNA 2401/4885MAPT 2705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.